Financial Survey: GENFIT S A/ADR (GNFT) versus The Competition

GENFIT S A/ADR (NASDAQ: GNFT) is one of 141 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare GENFIT S A/ADR to related businesses based on the strength of its profitability, analyst recommendations, institutional ownership, earnings, dividends, valuation and risk.

Earnings & Valuation

This table compares GENFIT S A/ADR and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
GENFIT S A/ADR $45.88 million -$72.96 million -2.81
GENFIT S A/ADR Competitors $736.87 million $133.15 million 3.09

GENFIT S A/ADR’s peers have higher revenue and earnings than GENFIT S A/ADR. GENFIT S A/ADR is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares GENFIT S A/ADR and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GENFIT S A/ADR Competitors -3,182.92% -153.94% -37.94%

Volatility and Risk

GENFIT S A/ADR has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, GENFIT S A/ADR’s peers have a beta of 1.32, suggesting that their average stock price is 32% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for GENFIT S A/ADR and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GENFIT S A/ADR 3 3 3 0 2.00
GENFIT S A/ADR Competitors 1378 4242 8513 390 2.54

GENFIT S A/ADR presently has a consensus target price of $12.20, indicating a potential upside of 120.22%. As a group, “Biological products, except diagnostic” companies have a potential upside of 22.75%. Given GENFIT S A/ADR’s higher possible upside, analysts plainly believe GENFIT S A/ADR is more favorable than its peers.

Insider & Institutional Ownership

2.9% of GENFIT S A/ADR shares are owned by institutional investors. Comparatively, 51.6% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 17.2% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


GENFIT S A/ADR peers beat GENFIT S A/ADR on 9 of the 13 factors compared.


Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.

Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with's FREE daily email newsletter.